Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Savara (SVRA)
NASDAQ:SVRA
Holding SVRA?
Track your performance easily
SVRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.82 - $5.70
Previous Close$3.36
Volume443.43K
Average Volume (3M)1.34M
Market Cap
$576.64M
Enterprise Value$383.79M
Total Cash (Recent Filing)$219.40M
Total Debt (Recent Filing)$26.55M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Mar 13, 2025EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding171,618,944
10 Day Avg. Volume2,647,303
30 Day Avg. Volume1,341,445
Standard Deviation0.38
R-Squared0.02
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)2.70
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.57
Forecast
1Y Price Target
$10.20Price Target Upside203.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Savara News
Bulls Say, Bears Say
Bulls Say
Approval And Market PotentialMolgramostim’s approval is highly likely and the diagnosed U.S. population is already larger than literature estimates.
Clinical Trial SuccessThe results look to be a best case scenario with convincing DLCO data, statistical significance on one key secondary and trends on the other two secondaries with clean safety.
Financial PerformanceSVRA shares look particularly attractive at the current market cap, and peak sales estimates appear conservative on multiple fronts.
Bears Say
Manufacturing RiskThe biggest risk to approval is manufacturing, as the current partner GEMA has never had a FDA approved product.
Market OpportunityThere is not sufficient evidence to justify a $500M US market opportunity for Molbreevi.
Market StrategyThere seems to be some reluctance among physicians regarding patient testing, which is concerning since one of Savara's main strategies is targeting physicians and increasing testing.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $2.81 and its highest was $5.70 in the past 12 months.
What is Savara’s market cap?
Currently, no data Available
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Mar 13, 2025 which is in 82 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Nov 12, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.109 by -$0.001.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -$0.11.
How many shares outstanding does Savara have?
Savara has 171,618,940 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.109. Following the earnings report the stock price went down -5.897%.
Which hedge fund is a major shareholder of Savara?
Among the largest hedge funds holding Savara’s share is Deerfield Management Company, LP. It holds Savara’s shares valued at 27M.
---
Savara Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.20 (203.57% Upside)
$10.20 (203.57% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 9.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $346.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.34%
12-Months-Change
Fundamentals
Return on Equity
-47.95%
Trailing 12-Months
Asset Growth
31.17%
Trailing 12-Months
Company Description
Savara
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
---
SVRA Stock 12 Month Forecast
Average Price Target
$10.20
▲(203.57% Upside)
Technical Analysis
Best Analysts Covering SVRA
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+32.85%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +32.85% per trade.
---